September 2009 Volume 5 Number 9
Visit Nature Reviews Rheumatology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=17&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Rheumatology online. To purchase a subscription, please
visit: http://links.ealert.nature.com/ctt?kn=78&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=54&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
*********************************************************************
Nature Reviews Rheumatology Impact Factor: 5.677*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Interested in Wnt signaling? Please take a look at these articles that
have recently appeared within the pages of Nature Reviews Rheumatology:
Osteoimmunology: Wnt antagonists: for better or worse?
Rik J. Lories, Frank P. Luyten
Wnt and PPAR [gamma] signaling in osteoblastogenesis and adipogenesis
Ichiro Takada, Alexander P. Kouzmenko and Shigeaki Kato
Wnt-[beta]-catenin signaling in the pathogenesis of osteoarthritis
Maripat Corr
The role of Wnt proteins in arthritis
Jochen Zwerina, Jean-Pierre David, Georg Schett
[beta]-Catenin in the race to fracture repair: in it to Wnt
David Silkstone, Helen Hong, Benjamin A Alman
http://links.ealert.nature.com/ctt?kn=17&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Rheumatology Study Day/Symposium,
23 September,
Royal College of Physicians of Edinburgh
Programme and registration details at:
http://links.ealert.nature.com/ctt?kn=94&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
or from: c.gray@rcpe.ac.uk
=====================================================================
"Officially endorsed by the Asia Pacific League of Associations for
Rheumatology"
----------------------
RESEARCH HIGHLIGHTS
----------------------
Rheumatoid arthritis: Hit the road, JAKs!
p465 | doi:10.1038/nrrheum.2009.151
http://links.ealert.nature.com/ctt?kn=24&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Smoking delays CIA onset in mice
p466 | doi:10.1038/nrrheum.2009.125
http://links.ealert.nature.com/ctt?kn=22&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Acute inflammatory arthritis: IL-1 Trap prevents and treats gouty arthritis
in a new mouse model
p466 | doi:10.1038/nrrheum.2009.156
http://links.ealert.nature.com/ctt?kn=20&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Connective tissue diseases: Elucidating the origins of lung fibrosis
p467 | doi:10.1038/nrrheum.2009.153
http://links.ealert.nature.com/ctt?kn=18&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
IN BRIEF
Imaging | Inflammation | Osteoarthritis | Vasculitis syndromes
p467 | doi:10.1038/nrrheum.2009.160
http://links.ealert.nature.com/ctt?kn=83&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Rheumatoid arthritis: An alternative to methotrexate?
p468 | doi:10.1038/nrrheum.2009.152
http://links.ealert.nature.com/ctt?kn=102&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
IN BRIEF
Rheumatoid arthritis | Osteoarthritis | Lyme arthritis | Connective tissue
diseases
p468 | doi:10.1038/nrrheum.2009.161
http://links.ealert.nature.com/ctt?kn=84&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Rheumatoid arthritis: Tenascin C: a candidate for chronic inflammation?
p469 | doi:10.1038/nrrheum.2009.132
http://links.ealert.nature.com/ctt?kn=26&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Rheumatoid arthritis: The immunoproteasome as an anti-inflammatory target?
p469 | doi:10.1038/nrrheum.2009.155
http://links.ealert.nature.com/ctt?kn=32&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Bone: Monitoring BMD after bisphosphonate treatment: is it worth it?
p470 | doi:10.1038/nrrheum.2009.129
http://links.ealert.nature.com/ctt?kn=36&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Metabolic bone diseases: Improving strength and balance helps prevent falls
p470 | doi:10.1038/nrrheum.2009.154
http://links.ealert.nature.com/ctt?kn=38&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Regenerative medicine: Skin and bones (and cartilage): the dermal fibroblast
connection
Rocky S. Tuan
p471 | doi:10.1038/nrrheum.2009.170
New research reports that primary human dermal fibroblasts seeded into
a three-dimensional biodegradable matrix can differentiate in vitro into
osteoblasts and chondrocytes, and form three-dimensional bone-like and
cartilage-like constructs, respectively. Is skeletal tissue engineering
from skin biopsy tissue on the horizon?
http://links.ealert.nature.com/ctt?kn=40&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Pain: Limitations of guidelines for low back pain therapy
Andrea D. Furlan and Vicki Pennick
p473 | doi:10.1038/nrrheum.2009.172
The latest guidelines from the American Pain Society (APS) provide a
comprehensive analysis of the evidence on the use of interdisciplinary
rehabilitation and surgical and interventional procedures for the treatment
and diagnosis of chronic low back pain. But will they have any impact on
clinical practice?
http://links.ealert.nature.com/ctt?kn=4&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Comorbidities: Should cancer screening be routine in rheumatoid arthritis?
Eric L. Matteson
p474 | doi:10.1038/nrrheum.2009.173
The degree to which the elevated risk of malignant lymphomas in patients
with rheumatoid arthritis (RA) is related to disease activity or to
therapy is uncertain. Evidence is mounting in support of a strategy of
more-intensive cancer screening in these patients.
http://links.ealert.nature.com/ctt?kn=41&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Therapy: The as-yet unfulfilled promise of p38 MAPK inhibitors
Susan E. Sweeney
p475 | doi:10.1038/nrrheum.2009.171
Clinical tests of the novel small-molecule inhibitor of p38[alpha] MAPK,
VX-702, have resulted in an all-too-familiar outcome: modest clinical
efficacy and transient inhibition of inflammatory markers. Why have
p38[alpha] inhibitors failed, and what can we learn about the regulation
of signal transduction pathways in inflammatory arthritis?
http://links.ealert.nature.com/ctt?kn=11&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Genetics: Every shared epitope allele for itself?
Diane van der Woude and Tom W. J. Huizinga
p477 | doi:10.1038/nrrheum.2009.174
What is the relationship between genetic and environmental risk factors
in predisposing for rheumatoid arthritis (RA)? A new study provides more
details on the interaction between the HLA DRB1 shared epitope (SE) alleles
and smoking in conferring the risk of autoantibody-positive RA.
http://links.ealert.nature.com/ctt?kn=8&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Therapy: Another bad break for proton-pump inhibitors?
Laura E. Targownik
p478 | doi:10.1038/nrrheum.2009.176
Medications that inhibit gastric acid secretion are standard co-therapy
with NSAIDs, but evidence is emerging of a link between prolonged use of
these agents and an increased risk of hip fracture.
http://links.ealert.nature.com/ctt?kn=15&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Genetics: Mutations in the IL1RN locus lead to autoinflammation
Cem Gabay and Gaby Palmer
p480 | doi:10.1038/nrrheum.2009.177
The results of two new studies suggest mutations in the gene encoding
the interleukin (IL)-1 receptor antagonist (IL-1Ra) are responsible for
a spectrum of childhood inflammatory disorders characterized by an imbalance
in IL-1 expression. What implications do these intriguing results have for
the diagnosis and management of IL1-driven inflammatory disorders?
http://links.ealert.nature.com/ctt?kn=59&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Paget disease: when to treat and when not to treat
Frederick R. Singer
Published online: 04 August 2009
p483 | doi:10.1038/nrrheum.2009.149
Patients with Paget disease are often asymptomatic, but some experience
considerable morbidity in the form of bone pain and skeletal deformity,
as well as a variety of regional complications. Bisphosphonates are an
effective treatment for Paget disease, but questions still need answering
as to when and when not to treat symptomatic and asymptomatic patients
with this potentially painful and deforming disease.
Abstract: http://links.ealert.nature.com/ctt?kn=87&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Prognostic factors in rheumatoid arthritis in the era of biologic agents
Alla Skapenko, Iryna Prots and Hendrik Schulze-Koops
Published online: 28 July 2009
p491 | doi:10.1038/nrrheum.2009.157
In patients with rheumatoid arthritis, the benefits of tight control of
inflammation to prevent or delay joint erosion are clear. Markers predictive
of erosive disease enable physicians to identify those patients who would
benefit most from aggressive therapy, thus avoiding unnecessary risks and
costs associated with this intensive treatment approach. This Review
discusses various prognostic factors as well as issues that confound their
identification and application.
Abstract: http://links.ealert.nature.com/ctt?kn=88&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=66&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Fracture prevention in men
Piet Geusens, Philip Sambrook and Willem Lems
Published online: 28 July 2009
p497 | doi:10.1038/nrrheum.2009.148
The risk of experiencing a fracture is lower in men than in women beyond
the age of 50 years, but the burden of fractures is, nevertheless,
substantial in men. This difference in fracture incidence is likely to
be accounted for by differences in bone-related and fall-related factors,
which are outlined, along with other data relating to the epidemiology,
pathophysiology and treatment options for osteoporosis in men, in this Review.
Abstract: http://links.ealert.nature.com/ctt?kn=85&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=63&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Idiopathic sensorineural hearing disorders in adults-a pragmatic approach
David L. George and Sagun Pradhan
Published online: 04 August 2009
p505 | doi:10.1038/nrrheum.2009.150
Sensorineural hearing disorders are more common in patients with rheumatic
disease than in the general population, so it is important that
rheumatologists know how to diagnose and treat these comorbidities. In
this Review, the categories of sensorineural hearing loss are introduced,
and diagnostic and therapeutic approaches for these disorders are outlined.
Abstract: http://links.ealert.nature.com/ctt?kn=86&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=45&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Resolution of pansclerotic morphea after treatment with antithymocyte globulin
Philip Song, Christopher Gocke, Fredrick M. Wigley and Francesco Boin
p513 | doi:10.1038/nrrheum.2009.159
Song and colleagues describe the diagnosis and treatment of a 50-year old
man with pansclerotic morphea with immune-mediated bone-marrow failure
and cytopenias. Although standard therapies for fibrotic skin disorders
were ineffective, the patient responded to T-cell-targeted treatment with
antithymocyte globulin.
Abstract: http://links.ealert.nature.com/ctt?kn=81&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=51&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
The evidence for non-pharmacological therapy of hand and hip OA
Kare B. Hagen, Geir Smedslund, Rikke H. Moe, Margreth Grotle, Ingvild Kjeken
and Tore K. Kvien
p517 | doi:10.1038/nrrheum.2009.158
Clinical guidelines and recommendations, as well as clinicians and patients,
consider non-pharmacological modalities to be the mainstay of treatment
for osteoarthritis (OA). Despite this consensus in opinion, however, the
evidence base for the non-pharmacological management of hand and hip OA
continues to lag far behind that for knee OA, which suggests that more
research is required to optimize the management of hand and hip OA.
Abstract: http://links.ealert.nature.com/ctt?kn=79&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=50&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
YOUR SCIENCE CAREER: WHAT NEXT?
Explore your options at The Source Event: London 25/09/2009 and Berlin
04/12/09. Throughout the day conference sessions and workshops will tackle
a range of science career issues. Running alongside this is a FREE career
fair where you can meet employers who are actively looking to recruit
scientists.
Register now at:
http://links.ealert.nature.com/ctt?kn=25&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=53&m=33939805&r=MTc2NDQ4MTc5OAS2&b=2&j=NTcyOTQzNTUS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
